Cytogen, Inc. Stock: price and insider trades · South Korea

Cytogen, Inc. is a Health Care company. Its directors and officers file their transactions with DART (FSS). Between 10 November 2025 and 10 November 2026, 3 insiders published 10 filings.

Both sides are active: 1 purchase and 6 sales, from 1 insider and 2 insiders respectively. The totals exclude 7 filings filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 1 board member.

With 10 filings in twelve months, the company is more active than the median of 7 filings across the 2,629 companies we follow on the same exchange. Since 2021, the database holds 28 purchases and 7 sales by insiders of the company.

The last insider purchase was made public on 2 September 2026, 69 days ago. Filings reach the DART (FSS) feed a median of 3 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.